Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
PepLib logo — Rethink Peptide Drug Discovery: Universal-Exact-Diverse

PepLib

Rethink Peptide Drug Discovery: Universal-Exact-Diverse

Founded 2017 China Zhuzhou, China 6 employees Series A Total: $220.00M Biotechnology, Health Care

General Information

Company Name PepLib
Founded Year 2017
Location China Zhuzhou, China
Employees 6
Industries Biotechnology, Health Care
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with PepLib . To contact PepLib , visit peplib.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does PepLib compare?

A PDF of PepLib and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting PepLib soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About PepLib

PepLib is a high-tech biopharmaceutical startup focused on revolutionizing the discovery of new peptide drugs. Established in 2017, PepLib is based in Zhuzhou, China, with a subsidiary in New Jersey, USA. The company's core platform, Peptide Information Compression Technology (PICT), boasts a groundbreaking ZSenithFive® peptide library, containing information on nearly half a billion peptides. In addition to PICT, PepLib has developed 4 complementary peptide discovery platforms, enhancing its capabilities for peptide drug discovery. Securing Series Pre-A financing of 100 million yuan (USD 16 million) in 2019 and Series A financing of 220 million yuan (USD 35 million) in 2021, PepLib is now aiming for Series Pre-IPO financing. With over 190 employees, more than 80% of which are dedicated to research and development, the company is committed to advancing innovation in the treatment of oncology and cardiometabolic diseases. Notably, their oncology programs are focused on the development of peptide drug conjugates (PDCs) and peptide radionuclide conjugates (PRCs). PepLib's recent Series A investment on 30th April 2021 attracted significant funding from investors including Cowin Capital, HighLight Capital, Legend Star, CAS Investment Management, 澳银资本, and Fortune Capital. With a strong financial backing and a focus on critical therapeutic areas, PepLib is poised to make a substantial impact in the biotechnology and healthcare industries.

Business keywords: Peptide Drug Discovery, Biopharmaceutical, High-tech, Innovation, Peptide Library, Series Financing, Oncology, Cardiometabolic Diseases, R&D, GPCR Targets, Drug Conjugates, Radionuclide Conjugates, High-throughput Screening, Cell-based Assays, Biochemical Assays

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A CNY220.00M 6
Cowin Capital HighLight Capital Legend Star
Cowin Capital, HighLight Capital +4
30 Apr 2021

PepLib Alternatives & Competitors

View All Alternatives
PepLib vs
Design Pharmaceuticals Inc.
Design Pharmaceuticals Inc. United States

Boundless GPCR drug discovery

Seed
3 employees
Biotechnology, Health Care
PepLib vs
DELIVER Therapeutics, Inc.
DELIVER Therapeutics, Inc. United States

Applying high throughput screening technologies to deliver novel therapeutics

7 employees
Biopharma, Biotechnology
PepLib vs
Resonant Sensors Incorporated
Resonant Sensors Incorporated United States

High throughput label-free analysis in a 96-well plate. ResoSens Ultra-Mab Pro will speed up your a...

Venture round
4 employees
Biotechnology, Health Care
View all alternatives

FAQ About PepLib

Rethink Peptide Drug Discovery: Universal-Exact-Diverse
PepLib was founded in 2017.
PepLib is headquartered in Zhuzhou, China.
PepLib operates in Biotechnology and Health Care. Its work centres on Peptide Drug Discovery, Biopharmaceutical, High-tech and Innovation.
PepLib has approximately 6 employees.
PepLib has completed 1 funding round, raising a total of $220.00M. The latest funding stage is Series A.
Top alternatives and competitors to PepLib include Design Pharmaceuticals Inc., DELIVER Therapeutics, Inc., Resonant Sensors Incorporated, BellBrook Labs, StemoniX. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
PepLib and Design Pharmaceuticals Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for PepLib , https://bouncewatch.com/company/peplib, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout